Business Context and Reporting Period
This Form 8-K Current Report was filed by Eledon Pharmaceuticals, Inc. (ELDN) on December 16, 2024. The filing addresses a specific corporate governance event regarding the amendment of the Chief Executive Officer's employment agreement.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. This report is limited to executive compensation adjustments.
Material Changes
On December 16, 2024, the Company amended the employment agreement of CEO David-Alexandre Gros, M.D. The primary change modifies the market value cap for his Performance Bonus:
- Threshold: The bonus payment threshold remains at $6 million when the Company's market value reaches $600 million.
- Maximum Payout: The maximum bonus has been increased to $15 million, payable if the market value reaches $1.5 billion.
- Calculation Method: The bonus amount between the threshold and maximum is determined using linear interpolation.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies beyond the specific terms of the executive compensation amendment.
Investor Verification Checklist
- Verify the current market capitalization of Eledon Pharmaceuticals relative to the new $1.5 billion bonus cap.
- Review the original employment agreement dated September 9, 2020, and the April 27, 2023 amendment to understand the baseline compensation structure.
- Confirm the definition of the "Measurement Period" within the employment agreement to determine the timeframe for achieving the market value targets.